New migraine drug shows promise in Real-World study
NCT ID NCT06409845
First seen Jun 11, 2026
Summary
This study looked at how well eptinezumab works and is tolerated for preventing migraines. It included 130 adults with episodic or chronic migraine. Researchers tracked changes in monthly migraine days over 3 to 12 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SISC
Florence, Florence, 50134, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eptinezumab
What this could lead to
If successful, this could confirm eptinezumab as an effective preventive treatment for people with frequent migraines.
What could go wrong
This is a completed observational study, not a large randomized trial. Results may not apply to all migraine patients, and individual responses can vary.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.